Henagliflozin
Henagliflozin is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes
Clinical Trials (7)
Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes
The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7